Arch Biopartners Inc.

Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for kidney injury and disease, specifically targeting acute kidney injury (AKI) and chronic kidney disease (CKD). Its lead drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials aimed at improving patient outcomes for AKI, which affects millions globally. Arch also advances a pre-clinical CKD platform focused on IL-32, a cytokine implicated in diabetic kidney disease. The company's programs address both acute and chronic kidney conditions, aiming to provide effective therapeutic options.